Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$1.94
-5.4%
$1.86
$1.21
$3.81
$47.91M0.68256,260 shs227,477 shs
OS Therapies Inc stock logo
OSTX
OS Therapies
$1.68
+6.3%
$1.74
$1.12
$7.00
$47.21MN/A776,360 shs291,735 shs
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
$2.20
$2.20
$0.56
$8.60
$15.98M2.33932,542 shs282,689 shs
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
$11.00
$11.00
$0.00
$12.48
$62.26M-0.112 shs99 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
+7.33%+3.54%+4.59%+22.02%+37.58%
OS Therapies Inc stock logo
OSTX
OS Therapies
+1.28%-2.47%-13.19%+0.64%+157,999,900.00%
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00%0.00%0.00%0.00%+10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.3713 of 5 stars
1.00.00.00.00.02.51.3
OS Therapies Inc stock logo
OSTX
OS Therapies
2.2208 of 5 stars
3.70.00.00.01.61.70.6
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.00
Hold$1.67-14.09% Downside
OS Therapies Inc stock logo
OSTX
OS Therapies
3.40
Buy$18.00971.43% Upside
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
0.00
N/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TTPH, VHAQ, AADI, and OSTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/30/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/24/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/9/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/15/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/22/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M1.91N/AN/A$4.29 per share0.45
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
$7.38M2.17N/AN/A$6.68 per share0.33
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)
OS Therapies Inc stock logo
OSTX
OS Therapies
-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
-$70.08M-$22.85N/AN/AN/A-798.18%-210.86%-121.73%N/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
-$610KN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
N/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
0.76
0.76
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
0.06
3.66
3.56
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
42.29%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
22.14%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
OS Therapies Inc stock logo
OSTX
OS Therapies
13.80%
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
5.70%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
75.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionOptionable
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A28.10 millionN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
1197.26 millionN/AOptionable
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
25.66 million1.40 millionNot Optionable

Recent News About These Companies

Viveon Health Acquisition Corp
Clearday, Inc. (CLRD)
VHAQ-R Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. (VHAQ-RT)

New MarketBeat Followers Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$1.94 -0.11 (-5.37%)
As of 07/15/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

OS Therapies stock logo

OS Therapies NYSE:OSTX

$1.68 +0.10 (+6.33%)
Closing price 04:00 PM Eastern
Extended Trading
$1.62 -0.05 (-3.27%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Tetraphase Pharmaceuticals stock logo

Tetraphase Pharmaceuticals NASDAQ:TTPH

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

Viveon Health Acquisition stock logo

Viveon Health Acquisition NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.